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Abstract
Background: The timed-sequential chemotherapy regimen consisting of etoposide, mitoxantrone
and cytarabine (EMA) is an effective therapy for relapsed or refractory acute myelogenous leukemia
(AML). We postulated that granulocyte colony-stimulating factor (G-CSF) might enhance the
cytotoxicity of EMA by increasing the proportion of leukemic blasts in S-phase. We added G-CSF
to EMA (EMA-G) for therapy of advanced high-risk AML patients.
Methods: High-risk AML was defined as refractory, relapsed or secondary to either an antecedent
hematologic disorder or exposure to cytotoxic agents. The patients were treated with one course
of EMA-G consisting of mitoxantrone and cytarabine on days 1–3, and etoposide and cytarabine on
days 8–10. G-CSF was started on day 4 and continued until absolute neutrophil count recovered.
Results: Thirty patients were enrolled. The median age was 51 years (range, 25–75). Seventeen
(61%) patients had unfavorable cytogenetic karyotypes. Twenty (69%) patients had secondary AML.
Ten (34%) had relapsed disease. Four (14%) had refractory AML. Three (10%) patients died from
febrile neutropenia and sepsis. Major non-hematologic toxicity included hyperbilirubimenia, renal
insufficiency, mucositis, diarrhea, nausea and vomiting, skin rash. A complete remission was
achieved in 13 (46%) patients. Median overall survival was 9 months (range, 0.5–66). Median
relapse-free survival (RFS) for those who had a CR was 3 months (range, 0.5–63) with RFS
censored at the time of allogeneic bone marrow transplantation or peripheral stem cell
transplantation for 6 of the patients.
Conclusions: EMA-G is a safe and efficacious option for induction chemotherapy in advanced,
high-risk AML patients. The activity of EMA may be increased if applied in patients with less
advanced disease.
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The promise of improved outcome with the use of hemat-
opoietic growth factors in the treatment of acute myelog-
enous leukemia (AML) has yet to be realized. In several
prospective trials, patients were randomized to either a
hematopoietic growth factor or a placebo after induction
chemotherapy in an attempt to accelerate neutrophil re-
covery and improve outcome. These studies consistently
show accelerated neutrophil recovery without an increase
in leukemic relapse in patients treated with either granu-
locyte colony stimulating factor (G-CSF) or granulocyte-
macrophage colony stimulating factor (GM-CSF). [1–4]
Unfortunately these studies have failed to consistently
show a benefit in terms of remission and survival when
administered in such an adjuvant fashion. [5,6]
The hematopoietic growth factors have also been studied
for their therapeutic benefits when given before chemo-
therapy. Both G-CSF and GM-CSF recruit quiescent leuke-
mic blasts into cell cycle thus rendering them more
susceptible to the S-phase specific cytotoxicity of cytarab-
ine. [7–13] Several studies suggest a potential therapeutic
benefit from administering hematopoietic growth factors
before starting cytarabine-based chemotherapy. [14–19]
However, the results of larger randomized trials have been
disappointing. [20–23] Not only have remission and sur-
vival rates not been increased but the direct effect of
growth factors on the untreated leukemia has led to severe
toxic reactions and death. [24–26]
Chemotherapy also recruits quiescent leukemic blasts
into cell cycle. Burke and colleagues demonstrated in an in
vitro model that following an initial cycle of chemothera-
py "humoral factors" are generated which are capable of
recruiting quiescent leukemic blasts into S-phase. [27] The
maximal recruitment occurred about 4 to 6 days after
chemotherapy was administered. To apply these observa-
tions clinically, patients were first treated with cytarabine
and daunorubicin. This initial cycle of chemotherapy was
then followed by either a second course of cytarabine on
day 10 or AMSA on days 8–10. This "timed sequential
therapy" achieved a complete remission rate of 88% in de
novo and 70% in secondary AML. [28] Timed sequential
therapy has been employed in relapsed and de novo acute
leukemia and achieves complete remission rates compara-
ble to those achieved with other salvage chemotherapeu-
tic regimens. [29,30]
The combination of timed sequential chemotherapy and
hematopoietic growth factors allows for an initial cytore-
ductive course of chemotherapy before starting growth
factors. The growth factor could then work with the other
"humoral factors" generated by chemotherapy to maxi-
mize recruitment of leukemic blasts into cell cycle. Few
studies have tested this approach. We report the results of
a clinical trial assessing the potential benefit of adding G-




All patients had AML defined according to the standard
French-American-British (FAB) cytologic and cytochemi-
cal criteria [47]. Patients were considered to have good-
risk cytogenetics if their karyotype revealed either t(8;21),
inv(16), t(16;16) or t(15:17). A normal karyotype defined
intermediate-risk cytogenetics. All other clonal abnormal-
ities were considered poor-risk. Patients were eligible for
this protocol if their leukemia was: 1) refractory to previ-
ous induction chemotherapy, 2) in first or subsequent re-
lapse after initial complete remission following induction
chemotherapy, 3) secondary to transformation from an
antecedent hematologic disorder, or 4) secondary to pre-
vious exposure to cytotoxic agents. All patients were over
18 years of age. Only patients with a performance status of
2 or less and no organ failure [less than grade 2 according
to the World Health Organization (WHO) grading sys-
tem] could enter the study, except if organ failure was re-
lated to the leukemia itself. Patients with leukemic
meningitis were excluded. All patients gave signed in-
formed consent and were treated on clinical protocols ap-
proved by the Cleveland Clinic Foundation's Institutional
Review Board.
EMA-G Regimen
The EMA regimen contains etoposide, mitoxantrone and
cytarabine administered in a timed-sequential fashion.
[32] We added G-CSF to the EMA regimen, thus EMA-G.
EMA-G consists of mitoxantrone 12 mg/m2 per day intra-
venous (IV) bolus for 3 days (day 1 to 3) with cytarabine
500 mg/m2 per day IV continuous infusion (CI) for 72
hours (day 1 to 3). Etoposide 200 mg/m2 per day IVCI for
72 hours and cytarabine 500 mg/m2 per day IVCI for 72
hours were administered on day 8 to 10. G-CSF 5 mg/kg
per day subcutaneouly was started on day 4 and contin-
ued until the absolute neutrophil count (ANC) rose above
0.5 × 109/L for two consecutive days (Fig. 1). Only one
course of EMA-G induction was given. Post remission
therapy included chemotherapy, allogeneic bone marrow
transplantation (BMT) or peripheral stem cell transplanta-
tion (PSCT) at the treating physician's discretion and
availability of a transplant donor.
All patients were cared for in semi-private rooms supplied
with HEPA filters on a regular oncology unit. All patients
received standard supportive care including blood com-
ponent support for severe cytopenias as previously de-
scribed.[31] Acyclovir 250 mg/m2 per day IV or 400–800
mg PO bid, allopurinol 300 mg PO qd and fluconazole
400 mg PO qd were administered prophylactically.Page 2 of 7
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Bone marrow aspirates and biopsies were obtained on day
8 of chemotherapy and then at the discretion of the treat-
ing physicians. When a bone marrow aspirate or biopsy
obtained on or after Day 14 contained 5% or more blast
cells, G-CSF was stopped.
Complete remission (CR) was achieved when the follow-
ing parameters were met: 1) bone marrow was normocel-
lular, containing <5% blasts, >15% erythroid cells, and
>25% normal granulocytes; 2) peripheral blood had neu-
trophils > 1.5 × 109/L, hemoglobin >11 gm/dl, and plate-
lets > 1 × 1011/L; 3) no evidence of extramedullary
leukemia, and 4) all of the above fulfilled for at least 4
weeks. Nonresponse to EMA-G induction was defined as
the absence of CR after one course of induction therapy.
Relapse was defined by the appearance of circulating
blasts or bone marrow blasts >5% in a patient previously
in complete remission.
Evaluation of Toxicity
Severity of treatment-related toxicity was graded accord-
ing to the WHO criteria (World Health Organization
Handbook for Reporting Results of Cancer Treatment,
1979.)
Statistical Analysis
The method of Kaplan and Meier was used to analyze
overall survival, relapse-free survival, time to neutrophil
recovery and time to platelet recovery. Exact 95% confi-
dence intervals (CI) based on the binomial distribution




From August 1994 to November 1996, 30 patients were
enrolled onto this study. One patient received high-dose
cytarabine instead of EMA-G for induction therapy after
enrollment and was therefore excluded from further anal-
ysis. Thus, 29 patients received EMA-G induction therapy
and are evaluable for treatment-related toxicity. Only 28
patients are evaluable for induction response since 1 pa-
tient was lost to follow-up shortly after receiving induc-
tion therapy (no evidence of persisting leukemia by the
post-induction bone marrow biopsy). The characteristics
of the evaluable patients are listed in Table 1. Twenty-
eight patients had cytogenetic studies of bone marrow as-
pirates. Most patients (61%) had unfavorable karyotypes.
The majority of patients (69%) had secondary AML trans-
formed from either MDS (n = 10), CML (n = 5) or other
myeloproliferative diseases (n = 4), or secondary to cyto-
toxic agents (n = 1). Overall, 15 patients with secondary,
but untreated, AML were enrolled. Four patients were en-
rolled with AML refractory to previous induction therapy,
and 10 were enrolled with relapsed AML.
Recovery of neutrophil and platelet counts
The median time from the start of chemotherapy to recov-
ery of an absolute neutrophil count exceeding 0.5 × 109/L
was 30 days (range, 19 to 47 days). Three patients died of
febrile neutropenia and sepsis during induction therapy.
The median duration of platelet transfusion dependence
was 30 days (range, 22 to 48 days).
Efficacy of Therapy
Twenty-eight patients are evaluable for treatment re-
sponse. Thirteen patients (46%, 95% CI 27%–66%)
Figure 1
Schema of EMA-G regimen.
Table 1: Characteristics of 29 patients with AML treated with 
EMA-G.
Patients 29
Median Age (years) 51
Range (25–75)
Male: Female 16:13







Stage of the disease
Untreated (all secondary) 15
Refractory 4
Relapsed < 1 year 5
Relapsed > 1 year 5Page 3 of 7
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with CR had secondary leukemia. Twelve patients (43%)
failed to achieve CR following induction treatment. One
of the non-responders had no evidence of leukemia after
induction treatment and proceeded to bone marrow
transplant before meeting all of the criteria for complete
remission. Three patients (10%) died during induction
treatment.
Of the 13 patients who achieved CR, 6 patients received
further consolidation chemotherapy (3 with high dose cy-
tarabine, and 3 with intermediate dose cytarabine com-
bined with daunorubicin, etoposide, or interleukin-2),
and 6 patients received either allogeneic BMT or alloge-
neic PSCT. One patient relapsed before any post-remis-
sion therapy was given. Of the 13 patients who did not
achieve CR, 1 received salvage chemotherapy, 2 received
allogeneic BMT, and 10 died due to rapid disease progres-
sion.
Survival
The median overall survival (OS) for all evaluable patients
is 9 months (range, 0.5–66 months). Median relapse free
survival (RFS) for those who achieved CR is 3 months
(range, 0.5–63 months) with 6 patients censored at allo-
geneic BMT or PSCT. At five-years of follow-up, 3 patients
(11%) were still alive. Two of them were in CR, one of
whom had allogeneic BMT and the other had high dose
cytarabine as post-remission therapy. The third patient is
alive with recurrent leukemia.
Treatment-related Toxicity
All patients experienced fever in the setting of severe neu-
tropenia. Fifteen (15%) patients had documented infec-
tions. Three patients (10%) died from febrile neutropenia
and sepsis. Other WHO grades III-IV toxicity included
mucositis (17%), diarrhea (17%), skin rash (14%), nau-
sea and vomiting (14%), bleeding (3%). Ten (34%) pa-
tients had reversible hyperbilirubinemia and 5 (17%) had
WHO grades III-IV renal insufficiency. Three (10%) pa-
tients experienced severe neurological toxicity (1 with sei-
zure, 2 with severe vertigo) but those complications
resolved shortly after the completion of induction thera-
py. GCSF was stopped in 1 patient due to persisting pe-
ripheral blasts. When G-CSF was discontinued the
peripheral blasts cleared and the patient achieved a com-
plete remission.
Discussion
Hematopoietic growth factors clearly increase the cytotox-
icity of cytarabine to leukemia cells in vitro. [33] Clinical-
ly, however, they fail to increase remission rates when
started from 24 to 48 hours before any chemotherapy.
[20–23] Potential explanations for the failure of growth
factors to improve results when administered in this fash-
ion may reflect either their adverse effect on a large leuke-
mic burden or the necessary delay to the onset of
chemotherapy. [34] In our study we started growth factors
after the initial leukemic burden was reduced and then
optimized the timing of a second course of chemotherapy
to take advantage of known leukemic blast cell-cycle ki-
netics. [27] Our results are comparable to those achieved
with other salvage chemotherapeutic regimens that em-
ploy high-dose cytarabine. [35–39]
Rather than use a standard high-dose cytarabine regimen
we employed the EMA chemotherapy protocol devised by
Archimbaud and colleagues. [40] This regimen is effective
in patients with relapsed and refractory AML with a re-
ported CR rate of 60%. In addition EMA avoids the cere-
bellar neurotoxicity of high-dose cytarabine. Recognizing
the potential value of hematopoietic growth factors,
Archimbaud and colleagues added GM-CSF to the EMA
regimen beginning on Day 4 of treatment. Unlike the cur-
rent report, however, GM-CSF was discontinued on Day
10 of treatment. Unfortunately the addition of GM-CSF
did not increase the CR rate when it was compared to pla-
cebo in a prospective randomized study in patients with
relapsed and refractory AML. [41] The results with EMA
and EMA plus GM-CSF are compared with our own results
in Table 2.
Clearly the patient population in our study was different
than the population studied in the other two studies em-
ploying the EMA regimen. Our population is older and a
majority of our patients had secondary AML. These two
characteristics are among the most predictive of a poor
outcome. Although 15 of our patients were untreated at
the time of study enrollment all 15 had secondary AML
and 5 of them had CML in blast crisis unresponsive to hy-
droxyurea therapy. The poor-risk features of our patient
population probably explain our relatively low CR rate
compared to other EMA studies but also confirm the effi-
cacy of our treatment protocol since remissions would
only be expected in 40–50% of untreated patients with
secondary AML receiving initial induction chemotherapy.
[42–44]
Our study did not demonstrate a significant advantage to
the addition of G-CSF to the EMA regimen. Potential rea-
sons include the possibility that G-CSF failed to increase
the population of leukemic stem cells in S-phase over that
achieved with chemotherapy alone. Alternatively recruit-
ment of blasts into S-phase may not increase cytotoxicity
to a clinically significant degree. Finally even if S-phase in-
creases cytotoxicity and G-CSF is effective in increasing the
proportion of blasts in S-phase these effects may not be
sufficient for patients with advanced leukemia. In the few
studies exploring the role of timed-sequential chemother-
apy as primary treatment for de novo untreated AML resultsPage 4 of 7
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and prolonged survival. [45,46]
An initial concern with EMA-G was the effect the concur-
rent administration of G-CSF and chemotherapy might
have on bone marrow recovery. However, the concern was
unfounded since the median time to neutrophil and
platelet recovery is not different than that noted with EMA
(Table 2). This observation suggests that G-CSF may be
administered concurrently with chemotherapy without an
increase in toxicity to normal residual bone marrow. Oth-
er studies utilizing hematopoietic growth factors adminis-
tered before and concurrently with chemotherapy also
demonstrate no adverse effect on bone marrow recovery.
[20–22]
Conclusions
The treatment of advanced high-risk AML patients re-
mains challenging. The use of EMA-G in the current study
failed to demonstrate a better CR rate than published data
of EMA alone or EMA with GM-CSF (EMA-GM). However,
the 46% CR rate achieved in our cohort of patients with a
higher proportion of secondary AML and older median
age suggests that the EMA-G regimen deserves further
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